The identification of novel biomarkers to predict treatment efficacy, and additional therapeutic targets to overcome drug resistance in HER2+/ER+ breast cancer, will be beneficial in facilitating the development of more efficacious therapies for the heterogeneous group of HER2+/ER+ breast cancer [8]. This evidence concerns the gene ERBB2 and breast carcinoma.